Epclusa Fact Sheet
Epclusa is a fixed-dose combination of two HCV-fighting drugs (sofosbuvir and velpatasvir) in one pill. In the United States, Epclusa is approved for people with all hepatitis C genotypes (1–6) who are 18 years of age and older.
Zepatier Fact Sheet
Zepatier is two hepatitis C virus-fighting drugs in one tablet. These drugs block different steps of the virus lifecycle. In the United States, Zepatier is approved for people who are over 18 years old with hepatitis C genotype 1 or genotype 4.
Solvaldi Fact Sheet
Sovaldi (sofosbuvir) is an HCV-fighting drug that must be used with other drugs. In the United States, Sovaldi is approved for people with hepatitis C genotypes 1, 2, 3, or 4 who are over 18 years old.
Daklinza Fact Sheet
Daklinza (daclatasvir) is an HCV-fighting drug that blocks different steps of the virus life cycle. In the United States, Daklinza is approved for people over 18 years old who have HCV genotype 1 or genotype 3 (although it has been used in other genotypes).
Ribavirin Fact Sheet
Ribavirin (RBV) is an HCV-fighting drug. RBV does not work by itself. Adding RBV to other drugs can increase the chance of being cured from HCV. In the United States, ribavirin is approved for children (3 to 18 years of age) and adults.
Adherence Fact Sheet
What is adherence? Adherence means sticking to something. It is often used to describe taking medicine without missing doses for as long as needed. Good adherence helps to maintain—or improve—your health. This fact sheet is about adherence to hepatitis C…
Olysio Fact Sheet
Olysio (simeprevir) is an HCV-fighting drug. It must be used with other drugs to treat hepatitis C. In the United States, Olysio is approved for people with hepatitis C genotype 1 who are over 18 years old.
Ending the HIV Epidemic (ETE) in NYS
Ending AIDS as an epidemic is not just the right thing to do for the health of New Yorkers – it’s also cost-effective. We simply can’t afford a status-quo approach to HIV.
Have a Heart, Save My liver!
February 14, 2013 – Today, on the occasion of Valentine's Day, Médecins du Monde and Treatment Action Group (TAG) are launching an action urging pharmaceutical giants Merck and Roche to drop their exorbitant prices for pegylated interferon, an effective hepatitis…
Letter to the EMA: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)
May 24, 2012 TO: Marco Cavaleri CC: Hans-Georg Eichler European Medicines Agency 7 Westferry Circus- Canary Whar London E14 4 HB United Kingdom RE: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783) Dear Dr. Cavaleri, We wish to draw…